Additional file 1: of Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)
Henri Roché
Jean-Christophe Eymard
Abderraouf Radji
Alain Prevost
Rafik Diab
Michele Lamuraglia
Ravaka-Fatoma Soumoudronga
Isabelle Gasnereau
Alain Toledano
10.6084/m9.figshare.7355576.v1
https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Biosimilar_filgrastim_treatment_patterns_and_prevention_of_febrile_neutropenia_a_prospective_multicentre_study_in_France_in_patients_with_solid_tumours_the_ZOH_study_/7355576
Table S1. Reasons for premature withdrawal (n = 294). Table S2. Most common planned CT therapies for patients with ST (analysis population; n = 1174). Table S3. Characteristics of treatment with Zarzio® during the study in patients with follow up (n = 1141). Table S4. Summary of adverse events (n = 62) experienced by ST patients during the study. (DOCX 22 kb)
2018-11-16 05:00:00
Biosimilar pharmaceuticals
Filgrastim
Febrile neutropenia
Real-world
Chemotherapy
Solid tumours
Guidelines recommendations
Observational study